drugset / Trial / NCT01685151

A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder

NCT01685151

Phase 3 Withdrawn Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy and safety of once a day ramelteon tablets for sublingual administration (TAK-375SL) in the maintenance treatment of bipolar 1 disorder.

Timeline

Start
2012-09
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown Subcutaneous

Indications